Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EDOLAS: Early Switch to DTG/3TC in HIV-1
NCT04979468Phase 3Unknown
- Sponsor
- Società Italiana Malattie Infettive e Tropicali
- Start
- Mar 2021
- Primary completion
- Apr 2023
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 3 trial of dolutegravir + lamivudine in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Società Italiana Malattie Infettive e Tropicali. Status: unknown.
02
Drugs
dolutegravir + lamivudine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT04979468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04979468.